5.09k followers • 18 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Bristol-Myers Squibb Company
Exact Sciences Corporation
Seattle Genetics, Inc.
Array BioPharma Inc.
Blueprint Medicines Corporation
Genomic Health, Inc.
Spectrum Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Foundation Medicine, Inc.
A new ETF is setting its sights on advancing the field of health care technology. ROBO Global Healthcare Technology and Innovation ETF is giving investors another option to capture innovation and growth within the space. Travis Briggs, ROBO Global CEO, discusses with Yahoo Finance's Akiko Fujita on "The Ticker."
As the US$72m market cap Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released another year of negative earnings...
Giovanni Caforio has been the CEO of Bristol-Myers Squibb Company (NYSE:BMY) since 2015. This analysis aims first to...
Chip Scarlett has been the CEO of Geron Corporation (NASDAQ:GERN) since 2011. This analysis aims first to contrast CEO...
Traders also look at the activity of short sellers for trading opportunities. Sometimes, stocks with a large amount of short selling activity could be potential candidates for short squeezes. Other times, ...
Bristol-Myers Squibb today was upgraded to buy by TheStreet.com's quantitative service. Let's see whether the technical analysts and the quants are in agreement. In the daily bar chart of BMY below, prices appear to have been hammering out a base pattern.
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
While recent pullback in Seattle Genetics, Inc’s (NASDAQ: SGEN ) shares presents an attractive entry point, there are several pipeline catalysts ahead, according to Oppenheimer. The Analyst Oppenheimer’s ...